Rituxan (rituximab) - Roche
IgM Variant of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits: A First Case Report from Thailand (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0783; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "An angiotensin II receptor blocker was initiated, followed by rituximab at a dose of 1 g for two cycles...Long-term follow-up is required to assess the durability of renal response and risk of progression. IF showed 2+ granular staining for IgM, 1+ staining for Lambda and negative for Kappa mesangial hypercellularity on PAS" 
Case report • Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Glomerulonephritis • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Lupus Nephritis • Metabolic Disorders • Monoclonal Gammopathy • Nephrology • Pulmonary Disease • Renal Disease • Type 2 Diabetes Mellitus
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4554474
 
Monthorn Laorwarakoon; Solos Jaturapisanukul
 
Oct 2, 2026
 
Prev Next